Proactive Investors - Run By Investors For Investors

Kazia Therapeutics substantial shareholder lifts interest to 17.4%

Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases.
Kazia Therapeutics substantial shareholder lifts interest to 17.4%
Edison Investment Research assigned Kazia an indicative valuation range of A$1.35–2.17 per share

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) substantial shareholder Hishenk Pty Ltd has reiterated its confidence in the biotechnology company’s oncology drug development by increasing its interest to 17.4% from 13.8%.

The holding of the Sydney-based investor was boosted to 10.835 million shares on June 26 with another 1.844 million shares accumulated.

Since October 3 last year Hishenk and related entities have participated in a placement and purchased shares on-market, increasing the holding from around 6.685 million shares.

Today Kazia traded up almost 4% to A$0.40.

READ: Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research

Edison Investment Research has recently assigned an indicative valuation range of A$84–135 million or A$1.35–2.17 per share for the company.

This follows identification of a higher maximum tolerated dose (MTD) from a Phase IIa study of its brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor GDC-0084 in glioblastoma (GBM).

The result may lead to improved efficacy in the ongoing expansion cohort and planned Phase IIb study.

READ: Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment

GBM multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

Kazia is developing GDC-0084, a brain penetrant PI3K inhibitor licensed from Genentech, and a third-generation benzopyran drug, Cantrixil.

A new collaboration with the Alliance for Clinical Trials in Oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.

Further data from the Cantrixil Phase I study in ovarian cancer expected in the second half of 2019.

View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

Related Articles

Medical scanner
February 09 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
A paper rocket is ready to launch on a surgeon's scissors
March 29 2019
The company hopes to improve its share price with ADAPT technology successes.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use